No hantavirus vaccine candidate has advanced to Phase 3 trials or completed the full regulatory pathway required for approval by late 2026, underpinning the market’s 94.5% implied probability of “No.” Authoritative sources confirm only preclinical or early-phase (Phase 1/2) DNA, mRNA, and viral-vector candidates under study as of mid-2026, with typical development timelines spanning multiple years absent extraordinary funding akin to Operation Warp Speed. Recent 2026 outbreaks have intensified research interest and prompted new preclinical work on neutralizing antibodies and multivalent constructs, yet these efforts remain far from licensure thresholds. Trader consensus aligns with established clinical and FDA processes; accelerated emergency authorization or unexpected trial breakthroughs could theoretically shift odds, though current evidence shows no such pathway.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% вероятность
$129,673 Объем
$129,673 Объем
31 дек. 2026 г.
6% вероятность
$129,673 Объем
$129,673 Объем
31 дек. 2026 г.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine candidate has advanced to Phase 3 trials or completed the full regulatory pathway required for approval by late 2026, underpinning the market’s 94.5% implied probability of “No.” Authoritative sources confirm only preclinical or early-phase (Phase 1/2) DNA, mRNA, and viral-vector candidates under study as of mid-2026, with typical development timelines spanning multiple years absent extraordinary funding akin to Operation Warp Speed. Recent 2026 outbreaks have intensified research interest and prompted new preclinical work on neutralizing antibodies and multivalent constructs, yet these efforts remain far from licensure thresholds. Trader consensus aligns with established clinical and FDA processes; accelerated emergency authorization or unexpected trial breakthroughs could theoretically shift odds, though current evidence shows no such pathway.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Открытие рынка: May 4, 2026, 10:39 AM ET
Объем
$129,673Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine candidate has advanced to Phase 3 trials or completed the full regulatory pathway required for approval by late 2026, underpinning the market’s 94.5% implied probability of “No.” Authoritative sources confirm only preclinical or early-phase (Phase 1/2) DNA, mRNA, and viral-vector candidates under study as of mid-2026, with typical development timelines spanning multiple years absent extraordinary funding akin to Operation Warp Speed. Recent 2026 outbreaks have intensified research interest and prompted new preclinical work on neutralizing antibodies and multivalent constructs, yet these efforts remain far from licensure thresholds. Trader consensus aligns with established clinical and FDA processes; accelerated emergency authorization or unexpected trial breakthroughs could theoretically shift odds, though current evidence shows no such pathway.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Объем
$129,673Дата окончания
31 дек. 2026 г.Открытие рынка
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No hantavirus vaccine candidate has advanced to Phase 3 trials or completed the full regulatory pathway required for approval by late 2026, underpinning the market’s 94.5% implied probability of “No.” Authoritative sources confirm only preclinical or early-phase (Phase 1/2) DNA, mRNA, and viral-vector candidates under study as of mid-2026, with typical development timelines spanning multiple years absent extraordinary funding akin to Operation Warp Speed. Recent 2026 outbreaks have intensified research interest and prompted new preclinical work on neutralizing antibodies and multivalent constructs, yet these efforts remain far from licensure thresholds. Trader consensus aligns with established clinical and FDA processes; accelerated emergency authorization or unexpected trial breakthroughs could theoretically shift odds, though current evidence shows no such pathway.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы